ACT Brief: AI-Driven Enrollment Results, Statistician Standards in Early Phase, and RNA Editing for Kidney Disease

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part two of her post-SCOPE X interview, Liz Beatty shared results from a Sanofi COPD study where AI-enabled sites screened patients 33% faster and achieved 100% enrollment success, including reviving a site that had been non-performing for over 100 days. The data demonstrates how precise patient matching and operational guidance translates into measurable enrollment acceleration.
• In a new Q&A building off her recent video interview, Sam Hinsley of Phastar discussed why statisticians raising standards across the development timeline is critical, particularly in early phase where foundation decisions determine entire program success. Hinsley highlighted the newly launched Early Phase ESIG, bringing together statisticians from academia and industry to share knowledge and advance approaches for complex diseases requiring innovative design methodologies.
• Ascidian Therapeutics and Eli Lilly entered a collaboration on RNA exon editing for monogenic kidney diseases, with Ascidian eligible to receive up to $1.9 billion in milestone payments. The platform addresses kidney disease genetics previously difficult to treat, with option to expand to additional disease targets.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.